Acta Pharmaceutica Sinica B
|
2026, 16(4): 2396-2419
• ORIGINAL ARTICLE •
A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function
Full
Rebecca L. Brouillette1,2, Frédérique Lussier1,2, Émile Breault1,2, Nathan Meneboo1,2, Malihe Hassanzadeh1,2, Victoria Tremblay1,2, Magali Chartier1,2, Élora Midavaine1,2, Laurence Ulrich1,2, Jérôme Côté1,2, Véronique Blais1,2, Christine E. Mona3,4, Jean-Michel Longpré1,2, Michel Grandbois1,2, Pierre-Luc Boudreault1,2,5, Martin Audet1,2, Élie Besserer-Offroy1,5,6,7, Philippe Sarret1,2,5
Affiliations
1 Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada;
2 Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, J1H 5N4, Canada;
3 Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA;
4 Jonsson Comprehensive Cancer Center, UCLA Health, Los Angeles, CA 90095, USA;
5 RECITAL International Partnership Lab, Université de Caen Normandie, 14000, Caen, France & Université de Sherbrooke, QC, J1H 5N4, Canada;
6 Interdisciplinary Research Unit for Cancer Prevention and Treatment - Anticipe, INSERM, U1086, Université de Caen Normandie, 14000 Caen, France;
7 François Baclesse Comprehensive Cancer Center, UNICANCER, 14000 Caen, France
doi: 10.1016/j.apsb.2025.12.043
Outline
Pepducins are synthetic membrane-tethered lipopeptides designed to allosterically modulate G protein-coupled receptor (GPCR) signaling. Here, we characterize a series of pepducins targeting the neurotensin receptor type 1 (NTSR1), revealing their complex and multifaceted modulation properties. Using BRET-based biosensors, we show that PP-001, a pepducin derived from NTSR1’s first intracellular loop, preferentially activates G protein over β-arrestin signaling while inhibiting NT binding, NT-induced β-arrestin recruitment, and NTSR1 internalization, thereby acting as biased allosteric agonist and negative allosteric modulator. PP-001 also promotes the formation of both homo- and heteromeric multi-receptor complexes. In vivo, PP-001 elicits potent, sustained hypotensive effects, reversible by the NTSR1 antagonist SR48692. Although the precise mechanism of pepducin-receptor interaction remains unclear, we identify a critical N-terminal RKK motif for PP-001’s biological activity. Finally, thermodenaturation assays using purified NTSR1, combined with mutagenesis and molecular docking, provide evidence for the role of the receptor’s H8 domain in direct pepducin interaction. Together, these findings highlight pepducins as versatile modulators of GPCR function and as valuable pharmacological tools for GPCR-targeted drug development.
Pepducin
/
Lipopeptide
/
Neurotensin receptor type 1 (NTSR1)
/
G protein-coupled receptor (GPCR)
/
Biased agonism
/
Allostery
/
Drug discovery
Rebecca L. Brouillette, Frédérique Lussier, Émile Breault, Nathan Meneboo, Malihe Hassanzadeh, Victoria Tremblay, Magali Chartier, Élora Midavaine, Laurence Ulrich, Jérôme Côté, Véronique Blais, Christine E. Mona, Jean-Michel Longpré, Michel Grandbois, Pierre-Luc Boudreault, Martin Audet, Élie Besserer-Offroy, Philippe Sarret.
A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function[J].
Acta Pharmaceutica Sinica B,
2026
, 16
(4)
: 2396
-2419
.
DOI: 10.1016/j.apsb.2025.12.043
Year 2026 volume 16 Issue 4
PDF
6
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.12.043
- Receive Date:2025-08-01
- Online Date:2026-09-17